通过 mitochondrial caspase 阻断,TP53 突变导致治疗耐药性
bioRxiv : the preprint server for biology
|September 5, 2025
概括
在急性髓性白血病 (AML) 中,TP53突变通过阻断酶激活而不是线粒体透,导致对 VenAza 治疗的耐药性. 这一发现揭示了克服TP53突变AML治疗耐药性的新治疗标.
科学领域:
- 血液学
- 分子生物学
- 癌症研究
背景情况:
- 急性髓性白血病 (AML) 是一种复杂的血液癌症,具有多种分子驱动因素.
- 在AML中,TP53突变与预后不佳和治疗耐药性有关,尤其是Venetoclax加Azacitidine (VenAza).
- 在TP53突变AML中,VenAza耐药性的确切机制尚不完全理解.
研究的目的:
- 调查Venetoclax加Azacitidine (VenAza) 在TP53突变/缺陷急性髓性白血病 (AML) 的分子基础.
- 阐明TP53突变对AML细胞的亡诱导途径的功能影响.
- 确定针对TP53突变AML的新疗法.
主要方法:
- 在VenAza治疗时,对TP53突变细胞与野生型AML细胞的p53信号通路激活的比较分析.
- 在同源性AML模型中评估G1停止,衰老和亡的功能性测试.
- 对线粒体外膜透 (MOMP) 和-3/7激活的评估.
- 对TP53突变原发性AML瘤的评估.
主要成果:
- 在治疗VenAza后,TP53突变/缺乏AML显示了p53通路上调的减少和亡诱导的受损.
- 虽然MOMP被保留,但TP53突变AML表现出有缺陷的卡斯巴-3/7激活,脱细胞灭绝阶段.
- 在TP53突变AML中,这种酶阻塞是VenAza和化疗耐药性的关键驱动因素.
- TP53突变的AML细胞表现出选择性失败而不是细胞周期停止.
结论:
- 在TP53突变AML中对VenAza的耐药性主要是由MOMP后的酶激活驱动的.
- 这种机制强调终端酶激活是TP53突变AML的一个关键漏洞.
- 在这种致命的AML亚型中,向酶激活提供了一种有前途的治疗途径来克服VenAza耐药性.
更多相关视频
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.8K
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
13.5K
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Electron Transport Chain: Complex I and II
15.0K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
15.0K
The Intrinsic Apoptotic Pathway
6.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
